Urotensin II promotes secretion of LTB₄ through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages

Dan Lu¹, Fen Peng¹, Jun Li¹, Jing Zhao¹, Xiaojin Ye¹, Binghan Li²,³,⁴,⁵, Wenhui Ding¹

1Department of Cardiology, Peking University First Hospital, Beijing, China
2Renal Division, Peking University First Hospital, Beijing, China
3Peking University Institute of Nephrology, Beijing, China
4Key Laboratory of Renal Disease, Ministry of Health, Beijing, China
5Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China

Submitted: 14 January 2017
Accepted: 10 April 2017

Arch Med Sci 2019; 15 (4): 1065–1072
DOI: https://doi.org/10.5114/aoms.2019.85197
Copyright © 2019 Termedia & Banach

Abstract

Introduction: Urotensin II (UII) is an important vasoactive peptide involved in the pathogenesis of atherosclerosis. Monocytes/macrophages play important roles in every step of atherosclerosis. Although UII has a chemotactic effect on monocytes, it is unclear whether UII regulates inflammatory responses in macrophages. The present study sought to explore whether UII can promote leukotriene B₄ (LTB₄) production by macrophages.

Material and methods: The mRNA expression level of LTB₄ and 5-lipoxygenase were determined by real-time polymerase chain reaction. The protein level of LTB₄ and 5-lipoxygenase expression was assayed by enzyme-linked immunosorbent assay and Western blot, respectively. Western blot analysis was also employed to determine the phosphorylated forms of Akt. Reactive oxygen species (ROS) level was detected by the fluorescent probe 2′,7′-dichlorofluorescin diacetate and fluorescence intensity was measured with a multiwell fluorescence plate reader.

Results: Urotensin II promoted LTB₄ release and increased 5-lipoxygenase expression in a concentration- and time-dependent manner in RAW264.7 cells. Leukotriene B₄ production and 5-lipoxygenase expression were decreased by blocking the UII receptor (UT) with urantide, eliminating ROS with N-acetylcysteine and diphenyliodonium, and inhibiting Akt phosphorylation with LY294002. UII significantly elevated ROS production, whereas urantide, N-acetylcysteine and diphenyliodonium substantially attenuated this effect. UII also enhanced Akt phosphorylation significantly, and this effect was potently inhibited by urantide, N-acetylcysteine, diphenyliodonium and LY294002.

Conclusions: Urotensin II may promote 5-lipoxygenase expression and LTB₄ release in RAW264.7 macrophages via UT-ROS-Akt pathways. These results indicate that UII may participate in macrophage activation and suggest a potential new mechanism underlying atherosclerosis.

Key words: urotensin II, leukotriene B₄, macrophages, 5-lipoxygenase, inflammation.

Introduction

Atherosclerosis, the leading cause of acute myocardial infarction and stroke, engenders enormous global health and economic burdens. It is
well established that atherosclerosis is a chronic inflammatory disease of the vascular wall [1]. Monocytes and macrophages have key functions in every phase of the atherosclerosis process, from the formation of the fatty streak to the destabilization and rupture of the plaque [2]. The recruitment and migration of monocytes to the vascular wall represents the hallmark of atherogenesis and requires complex interactions between cell adhesion molecules and chemotactic factors [2].

Urotensin II (UII), initially isolated from goby urophysis, has been regarded as one of the most potent vasoconstrictor peptides [3]. UII exerts various behavioral effects through binding to G-protein-coupled receptor 14, termed UT [3]. Increased plasma levels of UII and elevated expression of UII and UT have been demonstrated in several cardiovascular diseases, including essential hypertension, atherosclerosis, congestive heart failure and pulmonary hypertension [3]. In addition, UII and UT are predominantly expressed in atherosclerotic plaques of the aorta, the coronary arteries and the carotid arteries [3]. Clinical observations have revealed that UII levels are correlated with carotid plaque formation risk in patients with essential hypertension and type 2 diabetes [4, 5]. In vitro, in addition to promoting endothelial cells (EC) and smooth muscle cell (SMC) proliferation [6, 7], UII exerts a pro-inflammatory effect on vascular wall cells. Urotensin II has been reported to have a chemotactant effect on monocytes and can accelerate macrophage-derived foam cell formation [8, 9].

Our previous work revealed that UII upregulates the expression of 5-lipoxygenase (5-LO) in rat vascular adventitial fibroblasts [10, 11]. 5-LO is the key enzyme for the biosynthesis of leukotriene B$_2$ (LTB$_2$). LTB$_2$ is generated from arachidonic acid and is a potent chemoattractant that facilitates leukocyte adhesion and recruitment to endothelial cells, which plays a well-established role in the pathogenesis of atherosclerosis [11]. However, it is unclear whether UII regulates 5-LO expression and LTB$_2$ production in macrophages. In the present study, we explored the role of UII in regulating the 5-LO/LTB$_2$ axis in macrophages.

**Material and methods**

**Materials**

The reagents used in the study were purchased from the following suppliers: Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS) and trypsin (Gibco); UII (Phoenix Pharmaceuticals); urantide (Peptides International); Inverogen TRIZOL reagent (Life Technologies); High-Capacity cDNA Reverse Transcription Kit and SYBR Select Master Mix (Applied Biosystems); mouse LTB$_4$ ELISA kit (Cayman); antibodies against 5-LO, β-actin (CST), and β-actin (Beijing TransGen Biotechnology); LY294002 (CST); 2′,7′-dichlorofluorescein diacetate (DCFH-DA); N-acetylcysteine (NAC) and diphenyliodonium (DPI) (Sigma); goat anti-rabbit secondary antibody and rabbit antimouse secondary antibody (Beijing Zhongshan Golden Bridge Biotechnology), and SuperEnhanced chemiluminescence detection reagents (Millipore).

**Cell culture**

The RAW264.7 cell line was purchased from the Cell Center of Peking Union Medical College. The cells were cultured in DMEM containing 10% FBS, 100 mg/ml streptomycin and 100 units/ml penicillin at 37°C in a humidified atmosphere with 5% CO$_2$/95% air. After reaching confluence, the cells were passaged at a 1:4 to 1:6 ratio. All experiments were conducted using cells in the logarithmic growth phase.

**Enzyme-linked immunosorbent assay**

The ELISA was performed with a mouse LTB$_4$ ELISA Kit to assess the release of LTB$_4$ into the culture medium. Briefly, after treatment with the respective stimuli, 200 µl of culture medium was collected and then centrifuged to obtain the supernatant. The ELISA was conducted according to the manufacturer’s directions. The absorbance was read at 450 nm.

**Real-time PCR**

Total RNA was extracted from cultured RAW264.7 cells following the manufacturer’s directions and then reverse-transcribed into cDNA as described. Real-time PCR was performed using the ABI 7300 System (Applied Biosystems). The expression levels of β-actin and 5-LO were assessed using the following primer sequences: β-actin, F 5′-GGCCAACCGTGAAAAGATGA-3′ and R 5′-CTGTTCGTGATCCCCTTTTC-3′; and 5-LO, F 5′-GGCCAACCGTGAAAAGATGA-3′ and R 5′-CTGTTCGTGATCCCCTTTTC-3′. The relative mRNA levels of 5-LO in RAW264.7 cells were determined using the comparative threshold cycle (CT) method using the 2$^{-\Delta\Delta CT}$ equation. β-actin was used as an internal control gene. Three different experiments were performed for each experimental condition.

**Western blotting**

Cell lysates containing 30 µg of total protein were resolved by electrophoresis in a 10% sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel and transferred to a nitrocellulose membrane. After blocking with 5% nonfat milk, the membranes were probed with specific primary antibodies targeting 5-LO (1:1000 dilution), β-actin (1:5000 di-
Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages.

Measurement of ROS

Intracellular reactive oxygen species (ROS) production by RAW264.7 macrophages was determined using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA). The cells were pretreated with different stimuli for 1 h prior to exposure to UII for 2 h. Next, the cells were loaded with DCFH-DA (10 µM) and incubated at 37°C for 30 min, followed by triple washes with FBS-free medium. The fluorescence intensity was immediately read using a fluorescence plate reader with an excitation wavelength of 488 nm and an emission wavelength of 525 nm. The ROS levels were calculated as the relative increase compared with the control.

Statistical analysis

Values are expressed as the mean ± SEM. One-way analysis of variance was applied to determine the differences between groups. Student’s t test was used for multiple comparisons. The data were analyzed using SPSS Statistics 16.0 software (SPSS Inc. Chicago, USA). A p-value less than 0.05 was considered statistically significant.

Results

UII promotes LTB4 release in macrophages

To investigate whether UII could regulate LTB4 production in RAW264.7 macrophages, ELISA assays were performed. The results showed that UII was able to promote LTB4 production in a time- and concentration-dependent manner in RAW264.7 macrophages. As shown in Figure 1 A, when the cells were treated with 10^{-8} M of UII, LTB4 production was increased after 2 h of treatment, peaking at 24 h of treatment. As shown in Figure 1 B, LTB4 production was significantly increased after stimulation with different concentrations of UII for 24 h. The maximal response was reached at 10^{-8} M (Figure 1 B).

UII promotes 5-LO expression in macrophages

Because 5-LO is the rate-limiting enzyme in LTB4 generation, we also explored whether 5-LO is regulated by UII. We found that the expression of 5-LO was upregulated by UII in both a concentration- and a time-dependent manner. Figures 2 A and C show that 10^{-8} M UII promoted 5-LO mRNA and protein expression in a time-dependent manner, with peak levels reached after 24 h of treatment. Figures 2 B and D show that different concentrations of UII upregulated 5-LO mRNA and protein expression in cells, with the maximal response reached at a concentration of 10^{-8} M. The changes in 5-LO protein expression in response to UII correlated well with the UII-induced LTB4 production shown in Figures 1 A and B, indicating that the UII-induced LTB4 production may be 5-LO dependent. Thus, unless otherwise illustrated, UII was applied at 10^{-8} M for 24 h in the following experiments.

We next found that blocking UT with urantide (10 µM) significantly reduced the UII-induced 5-LO expression. These results indicate that UII promotes 5-LO expression in RAW264.7 macrophages via UT (Figures 2 B, D).

Involvement of ROS in UII-induced 5-LO expression and LTB4 release in RAW264.7 macrophages

Reactive oxygen species play important roles as signaling molecules in the pathophysiology of...
complex cardiovascular diseases [12]. UII has been demonstrated to promote NADPH oxidase-derived ROS generation [13]. Moreover, NADPH oxidase-derived ROS can regulate 5-LO expression and LTB₄ synthesis in murine alveolar macrophages [14]. To determine whether intracellular ROS participated in the UII-induced 5-LO expression in RAW264.7 macrophages. As shown in Figure 3 A, exposure of RAW264.7 macrophages to UII for 2 h resulted in a noticeable increase in dichlorofluorescin (DCF) fluorescence compared with the control, whereas pretreatment with urantide (10 µM) for 1 h prior to stimulation with UII (10⁻⁸ M) for 24 h clearly attenuated this effect. Further investigation revealed that elimination of ROS by NAC and DPI significantly inhibited UII-induced 5-LO expression at the gene and protein levels (Figures 3 B, C) as well as LTB₄ release (Figure 3 D). These results revealed that NADPH-derived ROS may be involved in UII-induced 5-LO expression in RAW264.7 macrophages.

**Akt mediates UII-induced expression of 5-LO and LTB₄ release in RAW264.7 macrophages**

UII regulates the production of inflammatory mediators by sequentially promoting ROS generation and activation of the Akt pathway [13]. 5-LO expression can be induced in monocyte cells by inflammatory stimuli via an Akt-dependent pathway [15]. To investigate whether the Akt pathway was involved in UII-induced 5-LO expression and LTB₄ release, we determined the phosphorylation status of Akt in RAW264.7 macrophages after UII
Urotensin II promotes secretion of LTB₄ through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages

Figure 3. Involvement of ROS in UII-induced 5-LO expression and LTB₄ release in RAW264.7 macrophages. A = Effect of the different inhibitors on the UII-stimulated generation of ROS. The cells were stimulated with UII (10⁻⁸ M) for 2 h after pretreatment with urantide (10 µM), NAC (10 mM) and DPI (10 µM) for 1 h and then incubated for 30 min with DCFH-DA (10 µM). B = Effect of NAC and DPI on UII-induced 5-LO mRNA expression determined by real-time PCR. The cells were stimulated with UII (10⁻⁸ M) for 24 h after pretreatment with NAC (10 mM) and DPI (10 µM) for 1 h. C = Effect of NAC and DPI on UII-induced 5-LO protein expression determined by western blot analysis. D = Effect of different inhibitors on LTB₄ release in the presence of UII (10⁻⁸ M) for 24 h

UII induces LTB₄ release in macrophages via the UT/ROS/Akt signaling cascade

We next sought to investigate whether the UT/ROS pathway is associated with UII-induced Akt activation. We pretreated RAW264.7 cells with urantide (10 µM), NAC (10 mM), DPI (10 µM) or LY294002 (10 µM) for 1 h prior to exposing the cells to UII for 10 min. We observed that blocking UT or scavenging ROS markedly inhibited UII-induced Akt phosphorylation (Figure 4), indicating that the UII-induced activation of Akt is UT/ROS dependent.

Taken together, our results reveal that UII is a pro-inflammatory factor that promotes 5-LO-dependent LTB₄ production. This effect is mediated through a novel UT/ROS/Akt pathway and may play a crucial role in adventitial inflammation.

Discussion

Monocytes/macrophages play crucial and direct roles in all atherosclerosis lesional stages. UII has chemotactic properties for monocytes, and LTB₄ has chemotactic activity for macrophages. However, the relationship between UII and LTB₄ in macrophages is unclear. In the present
study, we investigated whether UII could promote \(\text{LTB}_4\) release from a macrophage-like cell line, with a special focus on the relative mechanisms. We reveal for the first time that the pro-inflammatory factor UII induces 5-LO-dependent \(\text{LTB}_4\) production through the UT/ROS/Akt pathway in macrophages. The study suggests that UII may play a key role in macrophage activation.

\(\text{LTB}_4\) is an arachidonic acid metabolite that is produced via the 5-lipoxygenase pathway. It is also a pro-inflammatory mediator that is involved in the pathogenesis of certain inflamma-

**Figure 4.** Akt mediates UII-induced expression of 5-LO and \(\text{LTB}_4\) release in RAW264.7 macrophages. A – UII induces Akt phosphorylation in RAW264.7 macrophages at the indicated time points. The cells were exposed to \(10^{-8}\) M UII for 0 to 60 min. B, C – Effect of the different inhibitors on UII-induced 5-LO expression. The cells were pretreated with PD98059 (10 µM), SB203580 (10 µM) and LY294002 (10 µM) for 1 h prior to stimulation with UII (\(10^{-8}\) M) for 24 h. 5-LO mRNA expression (C) and protein level (B) were then detected by real-time PCR and western blot analysis, respectively. D – Effect of different inhibitors on 5-LO release in the presence of UII (\(10^{-8}\) M) for 24 h.

**UA** – urantide, **PD** – PD98059, **SB** – SB203580, **LY** – LY294002. The data are from three independent experiments and are expressed as the mean ± SEM. *P < 0.01 compared with control; #p < 0.01 compared with the UII (\(10^{-8}\) M) group.

**Figure 5.** Effects of different inhibitors on the phosphorylation level of Akt. The cells were stimulated with UII (\(10^{-8}\) M) for 10 min after pretreatment with urantide (10 µM), NAC (10 mM), DPI (10 µM), and LY294002 (10 µM) for 1 h. Total and phosphorylated Akt levels were determined by western blot analysis.

**UA** – urantide, **LY** – LY294002. The data are from three independent experiments and are expressed as the mean ± SEM. *P < 0.01 compared with control; #P < 0.01 compared with the UII (\(10^{-8}\) M) group.
Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages

Inflammation is a key component of various cardiovascular diseases [16]. 5-LO is the rate-limiting enzyme in LTB4 synthesis. 5-LO has been linked to the pathophysiology of atherosclerosis [17], and a 5-LO promoter polymorphism has been correlated with atherosclerosis [18]. 5-LO inhibition can reduce macrophage recruitment to atherosclerotic lesions and may contribute to the amelioration of lesion formation [19]. In the present study, we found that UII promoted LTB4 secretion and 5-LO expression in a time- and concentration-dependent fashion. UII at 10^{-8} M showed the maximal response at 24 h after the initiation of treatment but there was no effect on 5-LO mRNA expression when UII was applied at the concentration 10^{-5} M. We further found that UII at 10^{-7} M promoted 5-LO mRNA expression in a time-dependent manner, with the peak effect observed after 8 h of treatment; the response then decreased to the baseline level at 24 h (data not shown). At the protein level, however, 5-LO and LTB4 continued to increase after 24 h of 10^{-7} M UII stimulation. The discrepancy between 5-LO mRNA and protein levels after 10^{-7} M UII stimulation for 24 h suggests that the pathways and mechanisms by which 5-LO mRNA and protein are upregulated may be different. This regulatory mode is similar to the 4-hydroxynonenal (HNE)-induced expression of 5-LO [20], in which 5-LO mRNA expression peaked after 4 h of treatment and decreased gradually, but 5-LO protein was still increasing after 24 h of treatment. As 5-LO is the limiting enzyme for both LTB4 and LTC4 production [21], the pathways and mechanisms by which UII upregulates 5-LO expression in macrophages and UII may be involved in various biological effects on macrophages. Further studies need to be performed.

UII-induced ROS generation in RAW264.7 macrophages was confirmed by a method using DPI partially decreased the UII-induced phosphorylation of Akt in macrophages, suggesting that ROS and blockage of this production by NAC and DPI partially decreased the UII-induced ROS pathway. These data are also consistent with the findings reported by Djordjevic et al. for pulmonary artery smooth muscle cells (PASMCs) [13]. According to these data, antioxidant drugs may represent a new therapeutic target for the treatment of related inflammatory diseases.

5-LO expression is regulated in a complex manner that involves different signaling pathways. In particular, inflammatory stimuli induce 5-LO expression in monocyte cells through an Akt-dependent pathway [15]. Additionally, UII has been shown to activate the Akt signaling pathway [13, 22]. In the present study, UII-induced LTB4 release and 5-LO expression in RAW264.7 macrophages were dependent on Akt signaling but not MAPK signaling. This finding was not entirely consistent with previous results obtained using PASMCs or rat aortic adventitial fibroblasts, which indicated that UII-induced plasminogen activator inhibitor-1 (PAI-1) expression is mediated by the activation of MAPKs (mitogen-activated protein kinase) and Akt [13] and that UII regulates 5-LO expression through p38MAPK (p38 mitogen-activated protein kinase) and ERK (extracellular signaling regulatory protein kinase) pathways [10], respectively. This discrepancy suggests that the expression and regulation of 5-LO is cell type-specific and pathway-specific. We also found that UII induced the production of ROS and blockage of this production by NAC and DPI partially decreased the UII-induced phosphorylation of Akt in macrophages, suggesting that ROS affects the Akt signaling and 5-LO expression during the process.

In conclusion, our data demonstrate the ability of UII to promote LTB4 production in macrophages. This effect is most likely mediated by the UT-ROS-Akt signaling pathway. These results contribute to our understanding of the pro-inflammatory effects of UII and may provide new insights regarding the mechanism underlying the inflammatory processes of atherosclerosis.

Acknowledgments
This project was supported by the Doctoral Fund of the Ministry of Education of China (No. 20120001120010).
Conflict of interest

The authors declare no conflict of interest.

References

1. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1: 297-329.
2. Lagun JC, Aleget M. Regulation of gene expression in atherosclerosis: insights from microarray studies in monocytes/macrophages. Pharmacogenomics 2012; 13: 477-95.
3. Watanabe T, Arita S, Shiraishi Y, et al. Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Curr Med Chem 2009; 16: 350-63.
4. Suguro T, Watanabe T, Ban Y, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007; 20: 211-7.
5. Suguro T, Watanabe T, Kodate S, et al. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in type 2 diabetes. Clin Sci (Lond) 2008; 115: 327-34.
6. Shi L, Ding W, Li D, et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 2006; 188: 260-4.
7. Rodriguez-Moyano M, Diaz I, Dionisio N, et al. Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGF receptor transactivation. Cardiovasc Res 2013; 100: 297-306.
8. Segain J, Rolli-Der Kinderen M, Gerois N, et al. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 2007; 179: 901-9.
9. Watanabe T, Suguro T, Kanome T, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005; 46: 738-44.
10. Dong X, Ye X, Song N, et al. Urotensin II promotes the production of LTC4 in rat aortic adventitial fibroblasts through NF-kappaB-5-LO pathway by p38 MAPK and ERK activations. Heart Vessels 2013; 28: 514-23.
11. Aiello RJ, Bourassa PA, Lindsey S, et al. Leukotriene B4 receptor antagonism reduces monocyte foam cells in mice. Arterioscler Thromb Vasc Biol 2005; 25: 519-25.
12. Chen K, Keaney JF Jr. Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease. Curr Atheroscler Rep 2012; 14: 476-83.
13. Djordjevic T, BelAlba RS, Bonello S, et al. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005; 25: 519-25.
14. Coffey MJ, Serezani CH, Phare SM, et al. NADPH oxidase deficiency results in reduced alveolar macrophage 5-lipoxygenase expression and decreased leukotriene synthesis. J Leukoc Biol 2007; 82: 1585-91.
15. Lee SJ, Seo KW, Kim CD. LPS increases 5-LO expression on monocytes via an activation of Akt-Sp1/NF-kappaB pathways. Korean J Physiol Pharmacol 2015; 19: 263-8.
16. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005; 4: 664-72.
17. Poeckel D, Funk CD. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res 2010; 86: 243-53.
18. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidon-